Aurinia Pharmaceuticals AUPH Increase (decrease) in contract liabilities and current deferred income

Increase (decrease) in contract liabilities and current deferred income at other companies

Ionis PharmaceuticalsIONS

-$20.82M-51.8%

ALN

Alnylam PharmaceuticalsALNY

——

Other financials

Income statement

See full

Revenue$77.7M+24.4%

Gross profit$71.2M+32.1%

Operating income$41.4M+89.6%

Net income$34.4M+47.2%

EPS (diluted)$0.25+56.3%

Balance sheet

See full

Cash & equivalents$41.0M-38.3%

Total debt$85.2M-7.9%

Total equity$567.6M+62.1%

Total assets$724.0M+43.4%

Cash flow

See full

Operating cash flow$32.6M+2,405%

Valuation

See full

Market cap$2.39B+78.5%

Enterprise value$2.44B+78.3%

P/E8×-25.6×

P/S8×+2.6×

Profitability

See full

Gross margin89.7%+1.5pp

Operating margin41.7%+29.4pp

Net margin100%+83.9pp

Returns & leverage

See full

Return on equity65%+53.8pp

Debt / equity0.2×-0.1×

Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's increase (decrease) in contract liabilities and current deferred income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aurinia Pharmaceuticals's increase (decrease) in contract liabilities and current deferred income?: Aurinia Pharmaceuticals (AUPH) reported increase (decrease) in contract liabilities and current deferred income of $1.08M in Q1 2026.
How has Aurinia Pharmaceuticals's increase (decrease) in contract liabilities and current deferred income changed year-over-year?: Aurinia Pharmaceuticals's increase (decrease) in contract liabilities and current deferred income decreased by 75.1% year-over-year, from $4.34M to $1.08M.